| Literature DB >> 32565431 |
Nicklas Vinter1,2, Anne Sofie Frederiksen3, Andi Eie Albertsen3, Gregory Y H Lip4, Morten Fenger-Grøn5, Ludovic Trinquart6, Lars Frost7,2, Dorthe Svenstrup Møller3.
Abstract
OBJECTIVE: Electrical cardioversion is frequently performed to restore sinus rhythm in patients with persistent atrial fibrillation (AF). However, AF recurs in many patients and identifying the patients who benefit from electrical cardioversion is difficult. The objective was to develop sex-specific prediction models for successful electrical cardioversion and assess the potential of machine learning methods in comparison with traditional logistic regression.Entities:
Keywords: atrial fibrillation; gender; statistics
Mesh:
Year: 2020 PMID: 32565431 PMCID: PMC7307540 DOI: 10.1136/openhrt-2020-001297
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Baseline characteristics
| Women n=332 | Men n=790 | |
| Age, years | 71.0 (65.0–77.8) | 67.0 (60.0–73.0) |
| Body mass index, kg/m2 | 27.0 (24.1–31.8) | 27.8 (25.2–31.5) |
| Heart rate, min−1 | 93.0 (79.8–114.0) | 91.0 (74.0–115.0) |
| Alcohol overuse, n (%) | 23 (6.9) | 110 (13.9) |
| Prior cardioversion and/or RFA, n (%) | 99 (29.8) | 292 (36.9) |
| Comorbidity, n (%) | ||
| Hypertension | 195 (58.7) | 481 (60.9) |
| Diabetes | 28 (8.4) | 114 (14.4) |
| COPD | 58 (17.9) | 78 (10.1) |
| Clinical scores, n (%) | ||
| CHA2DS2-VASc | ||
| 0 | 23 (6.9) | 83 (10.5) |
| 1 | 10 (3.0) | 200 (25.3) |
| ≥2 | 299 (90.1) | 507 (64.2) |
| HAS-BLED | ||
| 0 | 63 (19.0) | 299 (29.0) |
| 1 | 192 (57.8) | 360 (45.6) |
| ≥2 | 77 (23.2) | 201 (25.4) |
| Blood tests | ||
| Thyroid-stimulating hormone, IU/L | 1.5 (0.9–2.4) | 1.6 (1.1–2.4) |
| Haemoglobin, g/L | 136.9 (127.2–148.1) | 148.1 (136.9–156.2) |
| eGFR, mL/min/1.73 m2 | 66.0 (54.0–81.0) | 72.0 (61.0–84.0) |
| Echocardiographic data | ||
| Left ventricular ejection fraction, n (%) | ||
| ≥40 % | 280 (84.6) | 592 (75.0) |
| <40% | 51 (15.4) | 197 (25.0) |
| Left atrial diameter, cm | 4.2 (3.8–4.5) | 4.3 (4.0–4.7) |
| Medication, n (%) | ||
| Antiarrhythmic drugs | ||
| Class Ic | 11 (3.4) | 27 (3.5) |
| Class III | 61 (18.8) | 142 (18.3) |
| Beta-blocker | 262 (80.6) | 573 (73.9) |
| Non-dihydropyridine channel blocker | 16 (4.9) | 50 (6.5) |
| Digoxin | 90 (27.8) | 124 (16.0) |
| ACEI or ARB | 148 (45.5) | 392 (50.6) |
Data are median (25%–75% percentiles) or counts (percentages).
Missing data: body mass index 0.5%; heart rate 1.0%; chronic obstructive pulmonary disease (COPD) 2.0%; thyroid-stimulating hormone 5.9%; haemoglobin 1.0%; estimated glomerular filtration rate (eGFR) 0.9%; left ventricular ejection fraction 0.2%; left atrial diameter 2.7%; antiarrhythmic drugs 2.0%; beta-blocker 2.0%; non-dihydropyridine channel blockers, 2.0%; digoxin 2.0%; ACE inhibitor (ACEI) 2.0%; angiotensin II receptor blocker (ARB) 2.7%.
CHA2DS2-VASc: Congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke, tia or thromboembolism, vascular disease, age 65-74 years, and female sex. HAS-BLED: Hypertension, abnormal renal or liver function, prior history of stroke, prior major bleeding, labile INR, age>65 years, and drugs or alcohol.
RFA, radiofrequency ablation.
Figure 1Importance score of predictor variables by sex. ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; Hgb, haemoglobin; LVEF, left ventricular ejection fraction; RFA, radiofrequency ablation; TSH, thyroid-stimulating hormone.
Figure 2Calibration plots. Agreement between predicted and observed probabilities of successful cardioversion in deciles of predicted odds.
Multivariable logistic regression models for successful cardioversion after electrical cardioversion
| OR (95% CI)* | |
| Women | |
| Age | 1.06 (0.83 to 1.35) |
| Atrial diameter | 0.85 (0.67 to 1.08) |
| Thyroid-stimulating hormone, IU/L | 1.23 (0.96 to 1.58) |
| Beta-blockers | 0.64 (0.36 to 1.15) |
| Diabetes mellitus | 0.49 (0.20 to 1.22) |
| Men | |
| Age | 1.05 (0.90 to 1.22) |
| Left atrial diameter | 0.74 (0.63 to 0.87) |
| LVEF <40% (vs ≥40 %) | 1.46 (1.02 to 2.08) |
| ACEI or ARB | 0.72 (0.53 to 0.97) |
Among women, 300 of 332 (90.4%) patients were complete cases, and among men, 717 of 790 (90.8%) patients were complete cases.
*ORs associated with 1 SD increase were reported. SD for women: age 9.91; atrial diameter 0.56; thyroid-stimulating hormone 1.93. SD for men: age 10.12; atrial diameter 0.57.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction.
Figure 3Comparison between machine learning and logistic regression of predicted probabilities of successful electrical cardioversion, by sex.